Related Experiment Video

Updated: Jul 3, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients

Juan Carlos Ferrer-García1, Eva Sanchez-Ballester, Raquel Albalat-Galera

  • 1Division of Diabetes, Consortium University General Hospital of Valencia, Spain. ferrer_juagar@gva.es

Journal of Cardiovascular Pharmacology and Therapeutics
|July 19, 2008
PubMed

Insights

Individualizing atorvastatin dosage in type 2 diabetes patients effectively lowered low-density lipoprotein cholesterol (LDL-C) to target levels within 24 weeks. This intensive lipid-lowering strategy proved feasible and well-tolerated for achieving cardiovascular goals.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes is associated with increased cardiovascular risk.
  • Achieving target low-density lipoprotein cholesterol (LDL-C) levels is crucial for managing cardiovascular risk in diabetic patients.
  • Statin therapy, particularly atorvastatin, is a cornerstone of lipid management.

Purpose of the Study:

  • To assess the feasibility of an intensive lipid-lowering strategy using atorvastatin in statin-naïve patients with type 2 diabetes.
  • To determine the proportion of patients achieving a target LDL-C level (<2.6 mmol/L) within 24 weeks.
  • To evaluate the efficacy and tolerability of individualized atorvastatin dosing based on baseline and target LDL-C levels.

Main Methods:

  • A prospective study involving 202 statin-naïve patients with type 2 diabetes.
  • Patients received a starting daily dose of atorvastatin tailored to their baseline and target LDL-C levels.
  • The primary endpoint was the percentage of patients reaching the LDL-C goal (<2.6 mmol/L) at 24 weeks.
  • Lipid profiles, including total cholesterol, LDL-C, HDL-C, and triglycerides, were monitored.

Main Results:

  • 66.5% of 188 patients completing the trial achieved the target LDL-C level within 24 weeks.
  • The proportion of patients reaching the target varied by atorvastatin dose: 75% (10 mg), 67% (20 mg), 58% (40 mg), and 59% (80 mg).
  • Atorvastatin significantly reduced total cholesterol (29%), LDL-C (35%), and triglycerides (22%), with a minor reduction in HDL-C (3%).
  • All tested doses of atorvastatin were well tolerated.

Conclusions:

  • Individualizing the starting dose of atorvastatin based on baseline and target LDL-C levels is a feasible and effective strategy.
  • This approach enables a significant proportion of type 2 diabetic patients to achieve their LDL-C goals within 24 weeks.
  • The study supports the use of tailored atorvastatin therapy for intensive lipid management in type 2 diabetes.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...